PharmaTelevision - BayBio's year and the impact of new regulations on the industry

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: BayBio's year and the impact of new regulations on the industry

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this interview, filmed at BioPharm in San Francisco, Dr Fintan Walton speaks with Matthew Gardner, President and Chief Executive Officer at BayBio, a non-profit trade association in Northen California

They discuss:

• BayBio's stability, funding and partnering in the financial crisis
• how investors are hesitating until the dust settles
• new regulations and how they will affect private equity
• effects beyond life science for innovation as a whole
• the new wave of products borne of recent partnering
• why the industry must change as regulations change
• the hope brought by the success of smaller companies

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

BayBio's stability, funding and partnering in the financial crisis

Fintan Walton :

Hello and welcome to PharmaTelevision news review here in San Francisco at BioPharm America. On this show I haveMatthew Gardner, who is President and CEO of BayBio an organization that's supports the member biotechnology companies in San Francisco Bay Area. Welcome to the show.

Matthew Gardner:

Thanks Fintan Walton , so is a pleasure.

Fintan Walton :

Matthew Gardner, 2009 it's been a landmark year. How is that affected the BayBio area?

Matthew Gardner:

Well it's certainly been a tough year for a lot of Life Sciences companies in Northern California. I think what've seen is that we've got to be really grateful for just holding up that we've held the ground relative to the economic around us and that we've seen that a lot of companies have just shut their doors and put folks back out on the street looking for their next gig [ph] and I think that -- of course that happens in this industry even in a good economy. And so I think the difference that we are seeing right now is that it's taking those folks longer to get back into their next role. And so during a flat period like this, again I think we do have to be grateful that we've held that ground fairly well, we still see good science coming out there, still new companies being started, the venture capital investing data actually looks surprisingly good and then in the second quarter we see a huge jump in partnering activity, so I think there are good signals out there, but you are right it's absolutely been a tough year.

Fintan Walton :

So Genentech, a company that was one of the founding biotechnology companies now wholly owned by a major pharmaceutical company, that's obviously another part of the story as well. So where is that fit in relation to the struggling biotech that's trying to start off now, today in San Francisco?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Matthew Gardner

President and Chief Executive Officer

Matthew Gardner is President and CEO of BayBio, the voice of the life science industry in Northern California, headquartered in South San Francisco.He has contributed content to a broad range of publications, from biotechnology articles in Manufacturing Today and Helix International magazines to white papers on enterprise development and innovation policy. Mr. Matthew Gardner previously held the position of Director of the Maryland Bioscience Alliance, in Rockville, Maryland. There, he was responsible for serving the Mid-Atlantic bioscience community. Mr. Matthew Gardner founded new programs for the Alliance's membership, including its Clinical Development Initiative and Venture Capital Task Force. During his tenure, he served as the regional liaison for the BIO 2003 Annual Convention. Prior to working for the BioAlliance, he was the North American Director of Business Development for the government of Queensland, Australia, including responsibility for biotechnology initiatives. While serving Queensland, he founded and chaired of the Queensland-United States Bioscience Business Council. Mr. Matthew Gardneris a current member of the American Association for the Advancement of Science (AAAS) and the American Society of Association Executives. In prior advisory roles,he served the Maryland Technology Development Center, the Career Transition Center of Montgomery County, Maryland, and the Australia America Association of Washington, DC. He earned his Bachelor of Arts in Political Science and his Master of Arts in History, both from the University of San Diego.

BayBio

BayBio is an independent, non-profit 501(c)(6) trade association serving the life science industry in Northern California. The staff and services of BayBio are paid primarily through memberships, sponsorships, and event registration fees. BayBio provides these services through representatives in South San Francisco and through coalition partners in Washington, DC. Through advocacy, membership services, programs and more, BayBio brings the world's greatest life science community to your fingertips. With the support of more than 450 member organizations, BayBio is delivering the next-generation association to you today.